Financings Material +

Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet

Charlotte’s Web Swaps $65M Debt for BAT’s 40% Stake as Medicare Pilot Kicks Off

By The Northwire Desk — AI Analysis Mar 30, 2026 · 22:59 CWEB · 0.89 CHARLOTTE'S WEB HOLDINGS, INC.

Executive Summary

Charlotte’s Web reported Q4 2025 revenue of $13.3M (up 4.7% YoY) and full-year 2025 revenue of $49.9M (up 0.5% YoY), marking the first annual revenue increase since 2021.
The company announced a definitive financing transaction with BAT DE Investments involving the conversion of a C$75.3M convertible debenture plus C$14.2M in accrued interest, alongside a US$10M private placement equity investment.
The transaction eliminates approximately US$65M in principal debt and halts ~US$12M in future interest accruals. BAT will receive ~110M new shares, representing ~40% of post-transaction outstanding common shares.
Q4 2025 net loss widened to $11.5M ($(0.07)/share) from $3.4M in Q4 2024, driven by a $1.3M inventory charge for legacy gummy disposal and continued operating losses. Full-year net loss was $29.7M.
Adjusted EBITDA for Q4 was -$4.4M and -$12.9M for FY2025. Cash and cash equivalents fell to $8.0M from $22.6M at year-end 2024.
Management highlighted launch partner status in the CMMI Medicare pilot program (effective April 1, 2026) and FDA clearance for DeFloria’s Phase 2 trial of AJA001 for autism spectrum disorder.
The transaction requires TSX and shareholder approval, targeted for the AGM/Special Meeting around May 28, 2026.

Material Impact

The BAT transaction is fundamentally transformative for the balance sheet, removing the company’s largest liability and stopping a significant interest drain. This eliminates near-term solvency risk tied to the convertible debenture.
The US$10M equity injection provides immediate liquidity to fund the CMMI Medicare pilot rollout and sustain operations while the company executes its path to cash flow positivity.
Despite the balance sheet repair, the underlying business remains unprofitable. Q4 gross margin compressed to 37.5% due to inventory write-downs, and SG&A remains high at $10.6M. The company continues to burn cash, and the $8.0M cash balance is thin without the BAT proceeds.
BAT’s ~40% ownership stake represents substantial dilution for existing shareholders and introduces a dominant strategic partner with board nomination rights. While this aligns long-term interests, it shifts control dynamics and caps near-term upside for minority holders.
The CMMI Medicare pilot is a genuine new revenue channel, but it is in early stages with no quantified financial guidance. Reimbursement adoption, patient enrollment, and CMS compliance will dictate actual impact.

CWEB · Price

Company Overview

Charlotte’s Web is a U.S.-based botanical wellness company specializing in hemp-derived CBD, minor cannabinoids, and low-dose THC products.
Flagship Project: The Brightside™ line of fast-acting, low-dose hemp-derived Delta-9 THC and CBN gummies, utilizing proprietary TiME INFUSION™ technology for 5-15 minute onset. This line targets the high-growth functional wellness and sleep markets.
Secondary Initiatives: Expansion into functional mushroom supplements, direct-to-consumer e-commerce optimization, and a strategic pivot toward medical/reimbursement channels via the CMMI Medicare pilot.
Clinical Pipeline: 33% equity stake in DeFloria, a joint venture developing AJA001, an FDA-cleared Phase 2 botanical drug candidate for irritability in autism spectrum disorder. Charlotte’s Web holds exclusive commercial manufacturing rights.

More from CHARLOTTE'S WEB HOLDINGS, INC.